Respiratory
Respiratory
Boehringer Ingelheim
has over 90 years
of heritage
in managing
respiratory diseases
Our focus is on improving the quality of life of patients
suffering from debilitating respiratory diseases and enabling them to maintain a
more independent life
INTRODUCTION
Respiratory
Boehringer Ingelheim has emerged as a leader in this disease area, having
launched several treatments in a range of respiratory conditions including asthma,
chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF). COPD
is a serious, progressive lung disease that limits airflow in the lungs. COPD is
preventable and treatable but not curable and by 2033 it is predicted to be the third
leading cause of death worldwide.1 An important goal in the management of
COPD is increaseing a patient's ability to live their life to the extent they love to
and keep active for longer.
1. What is chronic obstructive pulmonary disease (COPD)? World
Health Organisation.2013.
http://www.who.int/features/qa/48/en/
(accessed August 2018)
PC-TH-100292
Production date: Oct 2018
Production date: Oct 2018